Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma

Trial Profile

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs AU 011 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Aura Biosciences
  • Most Recent Events

    • 31 Jan 2019 Planned number of patients changed from 45 to 52.
    • 31 Jan 2019 Planned End Date changed from 1 Mar 2020 to 1 Jul 2021.
    • 31 Jan 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top